We set out to examine the relationship between metformin and the proposed neuroprotective effects by comparing its impact on AD incidence and death with that of other commonly prescribed diabetic medications, including sulfonylureas, glucagon-like peptide-1 (GLP-1) receptor agonists, and short-acting insulin. Here, GLP1R is linked to Alzheimer disease.